In this work the cellular internalization and the intracellular effects of (2-hydroxypropyl)-beta (HPBCD) and random methyl-beta cyclodextrin (RAMEB) on Caco-2
In the last decade, nanotechnological progress has generated new opportunities to improve the safety and efficacy of conventional anticancer therapies.
The recent work of Jarazo et al. demonstrates that HP-β-CD ameliorates the dopaminergic neuronal loss phenotype, confirming the therapeutic potential
The team of Motoyama in Kumamoto has recently published new results on folate-appended CDs in leukemia and ovarian cancer (1,2).
A patent application by Knut M. Wittkowski (ASDERA LLC, US) entitled “Use of cyclodextrins in diseases and disorders involving phospholipid
OrganoTherapeutics in collaboration with University of Luxemburg has published interestingin vitro and in vivo results on the effects of HPBCD
CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.
In this study, antibody–supermolecule conjugates, consisting of a tumor-specific antibody and acid-labile polyrotaxane containing methylated b-cyclodextrin (Me-PRX), were designed to
The plasma membrane microdomain lipid rafts have been found by researchers to be involved in the replication cycle of numerous
The scientists at University of Michigan Medical Center, Ann Arbor, MI published on a new application of hydroxypropyl beta-cyclodextrin (HPβCD)